Co-Diagnostics Inc
CODX
Company Profile
Business description
Co-Diagnostics Inc is a molecular diagnostics company. The company develops, manufactures, licenses, and commercializes reagents used for diagnostic tests that function via the detection and/or analysis of nucleic acid molecules (DNA or RNA), including molecular tools for detection of infectious diseases. CDI's low-cost system uses its tests to diagnose tuberculosis, Zika, hepatitis B and C, Malaria, dengue and others. The Company also uses its proprietary technology to design specific tests for its Co-Dx PCR platform and to locate genetic markers for use in applications other than infectious diseases.
Contact
2401 S. Foothill Drive
Suite D
Salt Lake CityUT84109
USAT: +1 801 438-1036
Sector
Healthcare
Stock type
Defensive
Industry
Medical Devices
Fiscal Year End
31 December 2026
Employees
115
Stocks News & Analysis
stocks
ASX healthcare giant rallies despite a fall in profits
Easing investor concerns and signalling a return to growth.
stocks
Weekly earnings wrap: BHP, CSL, NAB and more
Materials, banking, healthcare and retail heavyweights reveal diverging outlooks.
stocks
Chart of the Week: Our top dividend stock picks on the ASX
Highlighting key income opportunities on the ASX.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,296.40 | 11.70 | -0.13% |
| CAC 40 | 8,501.91 | 7.45 | -0.09% |
| DAX 40 | 26,091.33 | 37.03 | -0.14% |
| Dow JONES (US) | 53,463.05 | 119.65 | 0.22% |
| FTSE 100 | 10,743.35 | 15.31 | 0.14% |
| HKSE | 25,671.72 | 176.65 | 0.69% |
| NASDAQ | 26,331.09 | 41.38 | 0.16% |
| Nikkei 225 | 65,982.49 | 656.07 | 1.00% |
| NZX 50 Index | 13,921.55 | 8.12 | -0.06% |
| S&P 500 | 7,707.98 | 16.22 | 0.21% |
| S&P/ASX 200 | 9,083.90 | 17.90 | -0.20% |
| SSE Composite Index | 3,908.80 | 14.37 | 0.37% |